Beijing Hotgen Biotech Co.,Ltd. (688068.SH) announced that its subsidiary, Beijing Shunjing Biopharmaceutical Technology Co., Ltd., has successfully completed the first patient dosing in a Phase II clinical study for its self-developed innovative drug, SGC001 injection. The trial, titled "A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SGC001 Injection in Chinese Patients with Acute Anterior ST-Segment Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention (pPCI)," is led by Professor Huo Yong from Peking University First Hospital and Professor He Ben from Shanghai East Hospital. More than 20 hospitals across the country are participating in the study. The trial was initiated at Shanghai East Hospital in early 2026, and the first patient was enrolled and dosed on March 9, 2026, under the direction of Professor Fan Jiamao at Linfen Central Hospital in Shanxi Province.